T. Rowe Price Associates
IMRX icon

T. Rowe Price Associates’s Immuneering IMRX Stock Holding History

T. Rowe Price Associates’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.66M Buy
1,936,076
+106,888
+6% +$541K ﹤0.01% 1340
2026
Q1 		$9.64M Sell
1,829,188
-164,770
-8% -$845K ﹤0.01% 1227
2025
Q4 		$13.1M Buy
1,993,958
+195,176
+11% +$1.25M ﹤0.01% 1174
2025
Q3 		$12.6M Buy
+1,798,782
New +$9.34M ﹤0.01% 1170
2025
Q2 		– Sell
-659,009
Closed -$1M – 3096
2025
Q1 		$1M Sell
659,009
-108,115
-14% -$196K ﹤0.01% 1959
2024
Q4 		$1.69M Sell
767,124
-43,003
-5% -$89.2K ﹤0.01% 1726
2024
Q3 		$2.02M Sell
810,127
-49,247
-6% -$71.6K ﹤0.01% 1634
2024
Q2 		$1.1M Sell
859,374
-50,892
-6% -$83.7K ﹤0.01% 1857
2024
Q1 		$2.63M Sell
910,266
-2,467,834
-73% -$13.8M ﹤0.01% 1446
2023
Q4 		$24.8M Sell
3,378,100
-155,222
-4% -$1.03M ﹤0.01% 902
2023
Q3 		$27.1M Sell
3,533,322
-47,423
-1% -$436K ﹤0.01% 845
2023
Q2 		$36.3M Buy
3,580,745
+122,377
+4% +$1.18M 0.01% 791
2023
Q1 		$33.6M Sell
3,458,368
-161,192
-4% -$915K 0.01% 788
2022
Q4 		$17.6M Sell
3,619,560
-43,932
-1% -$389K ﹤0.01% 944
2022
Q3 		$52.5M Sell
3,663,492
-479,337
-12% -$3.81M 0.01% 633
2022
Q2 		$22.4M Buy
4,142,829
+577,356
+16% +$3.08M ﹤0.01% 1137
2022
Q1 		$23.1M Buy
3,565,473
+376,968
+12% +$3.62M ﹤0.01% 1196
2021
Q4 		$50.7M Buy
3,188,505
+74,480
+2% +$1.81M ﹤0.01% 1002
2021
Q3 		$81.2M Buy
+3,114,025
New +$83.7M 0.01% 835

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

T. Rowe Price Associates's IMRX Position: Q2 2026 in Review

T. Rowe Price Associates increased its Immuneering (IMRX) stake by 5.8% in Q2 2026, buying an estimated $541K and bringing the position to 1,936,076 shares worth $9.66M. The position accounts for ﹤0.01% of the portfolio, ranked #1340.

T. Rowe Price Associates first reported a position in IMRX in Q3 2021 and has held it in 19 quarters since. The position peaked at $81.2M in Q3 2021. 112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • T. Rowe Price Associates held 1,936,076 shares of Immuneering worth $9.66M as of Q2 2026.
  • T. Rowe Price Associates bought 106,888 Immuneering shares in Q2 2026, an estimated $541K.
  • Immuneering made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1340 holding.
  • T. Rowe Price Associates first reported a position in Immuneering in Q3 2021 and has held it in 19 quarters since.
  • T. Rowe Price Associates's Immuneering position peaked at $81.2M in Q3 2021.
  • 112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.